Varda Space Industries has partnered with United Therapeutics to test pharmaceutical manufacturing in microgravity, signaling a growing trend of commercial space-based production enabled by lower launch costs.

Key Points

• Varda Space Industries is testing whether drugs crystallize differently in microgravity to create improved pharmaceutical products.
• Falling launch costs and the use of reusable rockets are making orbital manufacturing increasingly viable for commercial applications.
• NASA plans to launch a nuclear reactor-powered spacecraft to Mars by the end of 2028 to advance interplanetary travel.
• Defense technology firm Anduril recently doubled its valuation to over $60 billion following a $5 billion funding round.
• Google and SpaceX are reportedly in discussions to launch orbital data centers, with an initial project launch targeted for 2027.

Why it Matters

The shift toward orbital manufacturing and data hosting reflects a broader transition where space is becoming a functional extension of the terrestrial industrial economy. As launch costs decline, companies are increasingly looking to leverage the unique environment of space to gain competitive advantages in pharmaceuticals, defense, and high-performance computing.